NAS:BLRX (Israel)  
BioLine Rx Ltd logo

BioLine Rx Ltd

$ 0.93 -0.0107 (-1.14%) 10:08 PM EST
P/E:
At Loss
P/B:
0.83
Market Cap:
$ 60.29M
Enterprise V:
$ 18.99M
Volume:
248.46K
Avg Vol (2M):
300.65K
Also Trade In:
Volume:
248.46K
Market Cap $:
60.29M
PE Ratio:
At Loss
Avg Vol (2-Month):
300.65K
Enterprise Value $:
18.99M
PB Ratio:
0.83
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consists of two clinical-stage therapeutic candidates - Motixafortide, a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, a legacy therapeutic product called BL-5010 for the treatment of skin lesions.
Name Current Vs Industry Vs History
Cash-To-Debt 16.51
Equity-to-Asset 0.83
Debt-to-Equity 0.05
Debt-to-EBITDA -0.13
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 34.45
9-Day RSI 30.06
14-Day RSI 31.62
6-1 Month Momentum % -12.79
12-1 Month Momentum % -43.82

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.58
Quick Ratio 4.58
Cash Ratio 4.48

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -83.9

Financials (Next Earnings Date:2022-11-18 Est.)

BLRX's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:BLRX

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -0.45
Beta 1.67
Volatility % 68.16
14-Day RSI 31.62
14-Day ATR ($) 0.096131
20-Day SMA ($) 1.18561
12-1 Month Momentum % -43.82
52-Week Range ($) 0.84 - 3.1499
Shares Outstanding (Mil) 61.52

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

BioLine Rx Ltd Filings

Document Form Filing Date
No Filing Data

BioLine Rx Ltd Analysis

Share your research

Headlines

See More
No news.